Hepatology International最新文献

{"title":"A comprehensive evaluation on the impact of MASLD on the prognosis of chronic hepatitis B-related hepatocellular carcinoma following hepatectomy: results from retrospective multicenter cohort study and meta-analysis.","authors":"Yiyu Chen, Yangyang Ou, Kang Chen, Tianyi Liang, Jiayong Su, Xinping Ye, Liang Ma, Ming Yao, Junjiang Guo, Liang Liang, Jianjun Li, Yuanneng Nong, Ji An Chen, Fei Huang, Tao Peng, Jian-Hong Zhong, Yihe Yan","doi":"10.1007/s12072-026-11151-y","DOIUrl":"https://doi.org/10.1007/s12072-026-11151-y","url":null,"abstract":"<p><strong>Background: </strong>Prognosis after radical hepatectomy for chronic hepatitis B (CHB) related hepatocellular carcinoma (HCC) is poor. Comorbidity of CHB and metabolic dysfunction-associated steatotic liver disease (MASLD) has grown increasingly common, with MASLD further modifying the hepatic microenvironment beyond HBV-induced injury. However, its impact on postoperative prognosis remains unclear.</p><p><strong>Methods: </strong>Combining a retrospective study with meta-analysis, this study systematically compared prognostic differences and influencing factors in 424 hepatectomy patients (MASLD-CHB-HCC group vs. CHB-HCC group) from multiple centers. Additionally, a meta-analysis involving 6653 patients was performed to further verify the prognostic effect of MASLD.</p><p><strong>Results: </strong>In this retrospective cohort study, the MASLD-CHB-HCC group showed significantly superior overall survival (OS) (p = 0.041) and recurrence-free survival (RFS) (p = 0.028) compared with the CHB-HCC group, with statistically significant differences. However, after performing propensity score matching (PSM) screening, no statistical differences were observed in OS (p = 0.220) and RFS (p = 0.190) between the two groups. This result is consistent with our meta-analysis conclusion. Cox regression analysis demonstrated that higher body mass index (BMI) was an independent factor associated with favorable survival. In subgroup analyses stratified by different BMI cutoffs, among non-lean patients, the MASLD-CHB-HCC group achieved better OS (BMI ≥ 23 subgroup: p < 0.001; BMI ≥ 25 subgroup: p < 0.001) and RFS (BMI ≥ 23 subgroup: p < 0.001; BMI ≥ 25 subgroup: p < 0.001).</p><p><strong>Conclusions: </strong>MASLD exerts differential impacts on survival prognosis in patients with CHB-HCC, with divergent effects observed between lean and non-lean subgroups stratified by BMI.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149181292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A real-world multicenter study of statins in compensated advanced chronic liver disease on hepatic decompensation and mortality outcomes.","authors":"Cheng Han Ng, N Apoorva Sasikumar, Margaret L P Teng, Vincent L Chen, Jimmy Che-To Lai, Karn Wijarnpreecha, Rahul Kumar, Apichat Kaewdech, Masayuki Ueno, Anand V Kulkarni, Ming-Hua Zheng, Akash Roy, Ken Liu, Chitchai Rattananukrom, Mazen Noureddin, Mohammad Shadab Siddiqui, Emmanuel Tsochatzis, Mark D Muthiah, Hirokazu Takahashi","doi":"10.1007/s12072-026-11164-7","DOIUrl":"https://doi.org/10.1007/s12072-026-11164-7","url":null,"abstract":"<p><strong>Background and aims: </strong>Statins exert pleiotropic effects, including antiinflammatory, endothelial, and antifibrotic actions, which may slow the progression of cirrhosis. However, their use in patients with compensated advanced chronic liver disease (cACLD) remains limited due to concerns regarding potential hepatotoxicity, and data specific to this population remains sparse.</p><p><strong>Methods: </strong>We conducted a retrospective, multinational cohort study of adult cACLD (LSM >10 kPa) patients using data from the Cirrhosis Outcome and Research Endeavor (CORE) consortium, across 13 centers in 8 countries. Baseline statin use was the exposure of interest. Associations with first and second hepatic decompensation, composite liver-related events, and all-cause and cause-specific mortality were assessed using Fine-Gray competing-risks regression across two sequentially adjusted multivariable models and an inverse probability of treatment weighting (IPTW) analysis.</p><p><strong>Results: </strong>Among 2267 patients, 786 (34.7%) were statin users. Statin use was independently associated with a lower risk of first decompensation (Model 1: sHR 0.64; Model 2: sHR 0.66; IPTW: sHR 0.56) and composite liver-related events (Model 1: sHR 0.61; Model 2: sHR 0.63; IPTW: sHR 0.50), with benefit most pronounced in the moderate-risk portal hypertension strata and MASLD subgroup. No association was observed with all-cause, liver-related, or cardiovascular mortality. Associations with second decompensation were inconsistent.</p><p><strong>Conclusion: </strong>In this large multinational cohort of cACLD patients, statin use was associated with reduced risk of hepatic decompensation and liver-related events, but not all-cause mortality. These findings support a potential benefit for statins in this population.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149181258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diverging rate and absolute burden patterns of liver cancer attributable to NASH: global evidence and China as a sentinel case.","authors":"Junpeng Luo, Xiao Qi, Yandan Wang","doi":"10.1007/s12072-026-11162-9","DOIUrl":"https://doi.org/10.1007/s12072-026-11162-9","url":null,"abstract":"<p><strong>Background: </strong>The Global Burden of Disease Study (GBD) category \"liver cancer due to non-alcoholic steatohepatitis\" is modeled, rather than clinically adjudicated. We quantified this burden and tested whether declining age-standardized rates could coexist with rising absolute caseloads in China.</p><p><strong>Methods: </strong>We analyzed the GBD 2023 estimates from 204 countries and territories for 1990-2023. Etiologic shares were reported without intervals because the matched posterior draws were unavailable. We used full-period log-linear trends, segmented trends with a 2019 cutoff sensitivity analysis, Shapley decomposition with parametric uncertainty, and Bayesian local-linear-trend projections to 2045.</p><p><strong>Results: </strong>Global incident cases increased from 15,752 (95% uncertainty interval, 12,069-19,989) to 45,669 (34,794-57,442); the age-standardized incidence EAPC was 0.54% (95% confidence interval, 0.46-0.62). The modeled etiologic share rose from 5.8% to 7.9%. In China, the age-standardized incidence rate declined (EAPC, -0.68%), but cases increased from 4660 to 10,201. Population growth, aging, and age-specific rate change contributed +1413, +5382, and -1254 cases, respectively; their 95% simulation intervals were +1157 to +1729, +4401 to +6,597, and -3134 to +448. Full-data and fit-through-2019 incidence projections for 2045 were similar.</p><p><strong>Conclusions: </strong>NASH-attributable liver cancer remains a minority of all liver cancer but is increasing. Absolute caseloads should accompany age-standardized rates in planning. Decomposition does not identify causal mechanisms.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149181311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristic geoepidemiology and phenotype of autoimmune hepatitis: an 8-year population-based study in Taiwan.","authors":"Jur-Shan Cheng, Kai-Feng Sung, Chi-Huan Wu, Chung-Wei Su, Cheng-Jen Chen, Cheng-Yu Lin, Tsung-Hsing Chen, Wei-Ting Chen, Wei-Pin Lin, Yi-Chung Hsieh, Jennifer Tai, Ya-Ting Cheng, Ming-Ling Chang","doi":"10.1007/s12072-026-11161-w","DOIUrl":"https://doi.org/10.1007/s12072-026-11161-w","url":null,"abstract":"<p><strong>Background/aims: </strong>Data on the geoepidemiology and phenotype of autoimmune hepatitis (AIH) among individuals in Asia are limited.</p><p><strong>Methods: </strong>AIH patients were identified from the Taiwan National Health Insurance administrative database (n=24,867,461) with the ICD-10 CM code K75.4.</p><p><strong>Results: </strong>A total of 8909 AIH patients (females, n=6018) were included. The average age- and sex-adjusted prevalence (2016-2023) and incidence rates (2017-2023) were 20.505 per 100,000 population and 4.739 per 100,000 population per year, respectively. The overall annual percentage changes for prevalence and incidence were 25.56% (p<0.0001) and 4.85% (p<0.0001), respectively. Compared with AIH patients in southern Taiwan, AIH patients in northern Taiwan accounted for the majority (72.70%) and were younger at diagnosis (54.17 vs. 55.62 years, p=0.0011). The 8-year liver cirrhosis (LC), hepatocellular carcinoma (HCC), liver transplantation (LT), mortality and LT-free mortality cumulative incidence rates (CIRs) were 19.21%, 3.78%, 1.48%, 21.12% and 20.93%, respectively. The 8-year CIRs for hypertension, hyperlipidemia and diabetes were 44.77%, 46.84%, and 32.24%, respectively, and these diseases were the most common extrahepatic diseases. Lower hepatic and cardiometabolic complications and mortality but higher autoimmune complication CIRs were detected in northern than in southern Taiwan AIH patients. Higher hepatic and autoimmune complications but lower cardiometabolic complications and mortality CIRs were detected in female than in male AIH patients. Sex, age, residency, income, hepatic complications, diabetes and hyperlipidemia were associated with LC; sex, age, LC, ascites and diabetes were associated with HCC; and sex, age, residency, income, diabetes, hepatic complications, hyperlipidemia, systemic lupus erythematosus, thyroid diseases, systemic sclerosis and non-HCC cancers were associated with LT-free mortality.</p><p><strong>Conclusion: </strong>In Taiwan, the prevalence and incidence rates of AIH have increased over time. Care tailored to the patient's sex, age, residency, income and different complications is needed to improve outcomes.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149136394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploratory analysis of transcriptionally active HBV-host chimeric transcript burden in patients with increasing HBsAg during long-term antiviral therapy.","authors":"Luqi Tang, Bingqiong Wang, Yameng Sun, Shuyan Chen, Guiwen Guan, Jialing Zhou, Tongtong Meng, Wentao Tan, Shuai Xia, Xiaojuan Ou, Jidong Jia, Xiaoning Wu, Hong You","doi":"10.1007/s12072-026-11154-9","DOIUrl":"https://doi.org/10.1007/s12072-026-11154-9","url":null,"abstract":"<p><strong>Background and aims: </strong>The longitudinal relationship between transcriptionally active hepatitis B virus (HBV) integration dynamics and serum hepatitis B surface antigen (HBsAg) during long-term antiviral therapy remains unclear.</p><p><strong>Methods: </strong>Patients with HBV-related fibrosis/cirrhosis who underwent at least one liver biopsy at baseline, week 78, or week 260 were enrolled. HBsAg increase was defined as either a ≥5% increase from baseline to week 208 or at least two ≥5% increases between consecutive available visits. A subset of 10 patients with serial liver RNA sequencing underwent integrated clinical, transcriptomic, and histopathological analyses. HBV-host chimeric transcripts were identified using ChimericSeq and verified by BLAST, and intrahepatic HBsAg was assessed by immunohistochemistry.</p><p><strong>Results: </strong>Overall, 31.8% (99/311) of patients met the criteria for HBsAg increase, while others were classified into the stable/decrease group. Lower baseline HBsAg and higher histologic activity index (HAI) were independently associated with HBsAg increase (both p < 0.05). In the serial-biopsy subset (n = 10), patients in the HBsAg increase group (4/4) showed increased HBV-host chimeric transcript burden at week 260 versus week 78, whereas the six patients in the stable/decrease group showed stable or reduced burden. Intrahepatic HBsAg immunohistochemistry showed persistent clustered cytoplasmic positivity, with transcriptomic analysis indicating downregulation of multiple immune-related pathways in the HBsAg increase group.</p><p><strong>Conclusion: </strong>About 31.8% of patients had HBsAg increase during antiviral therapy. Baseline HBsAg and HAI were associated with HBsAg increase during antiviral therapy. In the exploratory serial-biopsy subset, patients with HBsAg increase tended to exhibit an increase in transcriptionally active HBV-host chimeric transcript burden and persistent clustered cytoplasmic HBsAg positivity.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149136361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A simple clinical model for predicting multiple liver histologic injuries in obese individuals undergoing bariatric surgery.","authors":"Shumin Li, Ziyi Yang, Xin Huang, Mingwei Zhong, Shibo Lin, Teng Liu, Han Zhao, Shaozhuang Liu, Shigang Zhao, Zi-Jiang Chen","doi":"10.1007/s12072-026-11159-4","DOIUrl":"https://doi.org/10.1007/s12072-026-11159-4","url":null,"abstract":"<p><strong>Background: </strong>Metabolic dysfunction-associated steatotic liver disease (MASLD) is common among obese individuals undergoing bariatric surgery, but liver biopsy is invasive and existing noninvasive tools generally assess single histologic features. We aimed to develop and externally validate a simple framework for predicting multiple liver histologic injuries.</p><p><strong>Methods: </strong>We included 909 obese individuals undergoing sleeve gastrectomy with intraoperative liver biopsy in the training cohort and 186 temporally separated patients in the internal test cohort. Six separate outcome-specific binary classification models were developed, one for each histologic outcome: steatosis, hepatocyte ballooning, significant fibrosis, metabolic dysfunction-associated steatohepatitis (MASH), NAS ≥5, and at-risk MASH. Multiple machine-learning algorithms were evaluated, and the best-performing algorithm was selected for each outcome. A simplified three-variable TabPFN framework using alanine aminotransferase, homeostasis model assessment of insulin resistance, and peripheral monocyte ratio was developed, with one binary model for each outcome. External validation included two biopsy-confirmed cohorts (n = 103 and 217) and the U.S. NHANES cohort (n = 4,299) using elastography-based assessments.</p><p><strong>Results: </strong>The models demonstrated good discrimination for multiple histologic liver injuries in the test cohort, with ROC-AUCs ranging from 0.73 to 0.86 across outcomes. The simplified three-variable framework showed consistent external performance, achieving ROC-AUCs of 0.84 for ballooning, 0.86 for steatosis, 0.79 for significant fibrosis, and 0.75 for MASH. The framework demonstrated generalizability in the NHANES population.</p><p><strong>Conclusions: </strong>This externally validated framework may support noninvasive identification of multiple liver histologic injuries and perioperative liver risk stratification in individuals undergoing bariatric surgery, thereby improving the clinical accessibility of liver pathology assessment.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149136450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma proteomic signatures of biological aging and metabolic dysfunction-associated steatotic liver disease risk: a prospective cohort study.","authors":"Teng-Rui Cao, Li-Juan Wu, Xing-Hua Yang, Ning-Fei Fan, Jie Ding, Miao Gong, Xu-Man Feng, Yi-Han Li, Yu-Xiang Yan","doi":"10.1007/s12072-026-11155-8","DOIUrl":"https://doi.org/10.1007/s12072-026-11155-8","url":null,"abstract":"<p><strong>Background: </strong>Biological aging is associated with incident metabolic dysfunction-associated steatotic liver disease (MASLD), but the underlying proteomic mechanisms remain largely unknown. This study aimed to systematically characterize the plasma proteomic landscape and identify specific biomarkers that mediate the aging-MASLD axis.</p><p><strong>Methods: </strong>We analyzed the associations between four multi-dimensional biological aging indicators (telomere length, frailty index, Klemera-Doubal method biological age, and phenotypic age), 2911 plasma proteins, and incident MASLD among 52,131 UK Biobank participants. A rigorous two-stage analytical pipeline, integrating multivariable linear and elastic net regression, was applied to screen robust aging-related proteins. Cox proportional hazard regression models and mediation analyses were employed to assess their roles in MASLD risk, followed by comprehensive tissue and functional enrichment analyses to elucidate underlying biological mechanisms.</p><p><strong>Results: </strong>During a median follow-up of 13.60 years, 762 participants developed MASLD. All biological aging indicators were significantly linked to MASLD incidence. We identified distinct proteomic signatures for these biological aging indicators. Furthermore, multiple proteins significantly mediated the corresponding association, explaining 0.5 to 50.7% of the risk. Notably, 769 unique mediators were identified, anchored by a core signature of five shared proteins (AXL, CCL19, CPM, REN, and TNFRSF11B) across all four indicators. Enrichment analyses revealed a multi-organ origin (predominantly lung, adipose tissue, and arteries), highlighting the dominance of immune-inflammatory pathways.</p><p><strong>Conclusions: </strong>Plasma proteins partially mediate the increased MASLD risk driven by biological aging. These findings underscore the roles of systemic immune-inflammatory signaling, providing biomarkers for early risk stratification and potential novel therapeutic targets for aging-associated hepatic pathology.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149127273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"APASL Oncology 2026 Tokyo.","authors":"","doi":"10.1007/s12072-026-11129-w","DOIUrl":"https://doi.org/10.1007/s12072-026-11129-w","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149108746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Randomised trial of lifestyle interventions for improving metabolic dysfunction-associated steatotic liver disease.","authors":"Wouter Robaeys, Leen Jm Heyens, Liesbeth Bruckers, Joris Penders, Mathieu Struyve, Ger H Koek, Sven Ma Francque, Geert Kmm Robaeys","doi":"10.1007/s12072-026-11153-w","DOIUrl":"https://doi.org/10.1007/s12072-026-11153-w","url":null,"abstract":"<p><strong>Background and aims: </strong>Lifestyle modification is the cornerstone of treatment for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). To date, no published randomised controlled trials (RCTs) have provided a direct, head-to-head comparison between mobile (m)-health and structured, human-led dietitian coaching in the management of MASLD.</p><p><strong>Methods: </strong>In a single-centre, 12-month RCT, participants (n=297) were randomised into three arms: (1) minimal intervention therapy (MIT) (n=102), (2) lifestyle coaching (n=97), and 3) m-health (n=98). Steatosis was measured using the controlled-attenuation parameter (CAP™), steatohepatitis by aspartate aminotransferase (AST), and fibrosis by vibration-controlled transient elastography (VCTE™).</p><p><strong>Results: </strong>Across all three study arms, an equally (p=0.998) significant reduction in CAP™ was observed. The mean CAP™ change was -23.94 dB/m (95% CI [- 36.70; -11.17], p<0.001) for the MIT group, -23.66 dB/m (95% CI [- 36.08;-11.23], p<0.001) for the lifestyle coaching group, and -21.96 dB/m (95% CI: [- 35.77;-8.15], p=0.002) for the m-health group. Over the 12-month period, guidance via m-health resulted in a significant decrease in mean serum AST levels (- 2.81 U/L (95% CI [- 5.06;-0.57], p=0.014). None of the intervention methods had a significant effect on fibrosis.</p><p><strong>Conclusions: </strong>This study shows that all three lifestyle-guidance modalities produced comparable, significant reductions in liver steatosis over 12 months, with no significant differences between groups and no observed changes in liver stiffness. These findings support m-health as a feasible, scalable alternative in MASLD management, though multi-centre validation is warranted to confirm these outcomes. TRAIL REGISTRATIONS: (clinicaltrials.gov NCT05792488).</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149108816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From association to action: a pragmatic GHT trigger for risk-targeted care in ALD-ACLF.","authors":"Baodong Wang, Jiayuan Huang, Zhiyun Chen","doi":"10.1007/s12072-025-10968-3","DOIUrl":"10.1007/s12072-025-10968-3","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1508-1509"},"PeriodicalIF":7.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145603644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}